This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders  • Bullous Diseases  • Pemphigoid  • Drug Therapy  • Drug Therapy, Other  • Immunologic Disorders  • Immunology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Marked Improvement in Depletion of Circulating Autoantibodies

Annette Czernik, MS; Jean-Claude Bystryn, MD

Arch Dermatol. 2008;144(5):658-661.

Background  Various antibody-mediated autoimmune disorders are treated with intravenous immunoglobulin (IVIg). While the exact action of IVIg is unknown, it likely acts to rapidly and selectively lower the level of pathogenic antibodies. The most effective use of IVIg, an expensive and potentially toxic treatment of autoimmune disorders, remains undetermined. We propose that the addition of immunosuppressive agents to the IVIg regimen may increase the ability of IVIg to lower the level of pathogenic antibodies.

Observations  For 16 months, we observed a 78-year-old patient with autoantibody-mediated bullous pemphigoid who was treated with IVIg and an adjuvant therapy on 2 separate occasions as well as IVIg alone on 2 other occasions. We observed the greatest depression of bullous pemphigoid antibodies when IVIg was combined with an immunosuppressive agent.

Conclusion  These results support the hypothesis that agents that suppress antibody synthesis can offset the rebound in the level of individual antibody that follows their depletion and thus can improve the effectiveness of IVIg treatment while reducing the cost and the potential toxic effects of therapy.

Author Affiliations: Department of Dermatology, New York University School of Medicine, New York.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?